34th Annual New Treatments in Chronic Liver Disease CME Conference

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

Tickets: https://go.evvnt.com/311090-0?pid=154

Time: 12:30 to 11:30

Prices:
Physicians: USD 350.0,
Non-Physicians: USD 280.0,
Fellows and Residents: USD 175.0,
Pre-Conference: USD 100.0

Speakers: Paul J. Pockros, MD, FACG, Scripps Clinic , Catherine T. Frenette, MD, FAST, AGAF, Scripps Clinic , Terry D. Box, MD, University of Utah School of Medicine, Paul Kwo, MD, Stanford University Medical Center, Cynthia Levy, MD, FAASLD, University of Miami, Miller School of Medicine, Michael R. Lucey, MD, University of Wisconsin School of Medicine and Public Health, Christian B. Ramers, MD, San Diego State University, School of Public Health, Yuki Rosenkoetter, PAC, MPAS, Scripps Clinic, Baylor College of Medicine, Norman L. Sussman, MD, Baylor College of Medicine, I. Raymond Thomason, MD, University of Utah, Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD, Inova Fairfax Hospital Center for Liver Disease